Description
Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family of lipid kinases. It is a pyrimidine derivatives compound discovered by Exelixis Inc. It has potential antineoplastic activity. It binds to class 1 PI3Ks in an ATP-competitive manner by inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and inhibiting the activation of the PI3K signaling pathway